Related Experiment Videos
Targeting TGF-β1 suppresses survival of and invasion by anaplastic thyroid carcinoma cells
Wenhai Sun1, Yanyan Xu2, Cheng Zhao3
1Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University Qingdao, China.
Background And Aims:
Overexpression of transforming growth factor (TGF)-β1 has been implicated in promoting cell survival, migration and invasion in many cancers, including anaplastic thyroid cancer (ATC). In the present study, we studied the effect of suppressing TGF-β1 by RNA silencing on the survival, invasion and metastasis of ATC cells.
Methods:
Small interfering RNA (siRNA) constructs targeting TGF-β1 were validated and used to develop clonal derivatives of the ATC cell line, 8505C. The cells were used in several in vitro assays, including migration, invasion, survival rate, colony formation and apoptosis. A wound healing assay was used to determine the migration of cells in culture and a Boyden chamber transwell assay was used for invasion. Further, clones were used in an in vivo mouse model to study the kinetics of tumor growth and metastatic growth in lungs.
Results:
Targeting TGF-β1 expression in 8505C cells caused a 70% decrease in migration and a 78% decrease in invasion, as well as a 68% decrease in proliferation and a 19% increase in apoptosis in vitro. The growth of primary tumors in vivo was also inhibited when compared with parental 8505C cells; however, the number of mice bearing lung metastases was not significantly decreased.
Conclusions:
Targeting TGF-β1 may be effective in inhibiting primary tumor formation, but not metastasis, by ATC cells. TGF-β1 inhibition in combination with other tumor-targeted therapies may be more effective in inhibiting ATC.
Insights
Suppressing transforming growth factor-beta 1 (TGF-β1) in anaplastic thyroid cancer cells reduced primary tumor growth and spread. However, TGF-β1 inhibition alone did not prevent lung metastasis, suggesting combination therapies are needed.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Transforming growth factor-beta 1 (TGF-β1) overexpression is linked to increased survival, migration, and invasion in anaplastic thyroid cancer (ATC).
- Targeting TGF-β1 is a potential therapeutic strategy for ATC, a highly aggressive cancer.
Purpose of the Study:
- To investigate the efficacy of RNA silencing to suppress TGF-β1 in ATC cells.
- To evaluate the impact of TGF-β1 suppression on ATC cell survival, invasion, and metastasis.
Main Methods:
- Small interfering RNA (siRNA) targeting TGF-β1 was used to create modified 8505C ATC cell lines.
- In vitro assays included migration (wound healing), invasion (Boyden chamber), proliferation, colony formation, and apoptosis.
- An in vivo mouse model assessed primary tumor growth and lung metastatic kinetics.
Main Results:
- TGF-β1 suppression led to a 70% decrease in migration and a 78% decrease in invasion.
- In vitro proliferation decreased by 68%, while apoptosis increased by 19%.
- Primary tumor growth was inhibited in vivo, but lung metastasis was not significantly reduced.
Conclusions:
- Targeting TGF-β1 effectively inhibits primary ATC tumor formation and reduces invasion and migration.
- TGF-β1 inhibition alone is insufficient to prevent ATC metastasis to the lungs.
- Combination therapies involving TGF-β1 inhibition may offer a more effective strategy against ATC.